Resilinc Special Report

Transformation in the Life Sciences Supply Chain Fueled by FDA PreCheck Rollout, the CGT Market, and More

Resilinc’s special report delivers a timely and strategic analysis of the evolving life sciences supply chain, spotlighting key trends in FDA PreCheck, continuous manufacturing, smart cold chain logistics, and cell and gene therapy (CGT) infrastructure. This 2025 supply chain outlook explores how regulatory changes and advanced technologies are reshaping how drugs are produced, monitored, and delivered. As biologics and CGTs introduce new demands, manufacturers and supply chain leaders must rapidly evolve to stay ahead of disruption and maintain operational agility. This report offers practical insights and actionable recommendations to build resilience and drive innovation in the face of accelerating change.
Key Insights:
  • Only 11% of manufacturers producing Active Pharmaceutical Ingredients (APIs) for FDA-approved products are based in the United States
  • The CGT supply chain and cold chain market is currently valued at approximately $1.5B and is projected to reach $4.4B by 2034
  • Between 2018 and 2024, temperature-controlled pharmaceutical products grew 21% faster than non-cold-chain drugs, driven by rising demand for biologics and CGTs